m+Medelevator.RU
← Поиск публикаций
Anti-cancer drugs · 2026

Macrophage-associated epithelial-mesenchymal transition in human breast cancer: contextualizing innate immune sensing programs.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lehrer Steven, Rheinstein Peter

Аннотация

To determine whether innate immune-sensing activity is associated with epithelial-mesenchymal transition (EMT) and related tumor-aggressiveness programs in human breast cancer. We analyzed RNA sequencing and clinical data from The Cancer Genome Atlas breast cancer cohort (n = 1087). Gene expression-based signatures were constructed for innate immune sensing, interferon signaling, CD8 T cells, macrophages, EMT, invasion, and metastasis. Associations were evaluated using Pearson correlation, Cox proportional hazards models, and multivariable linear regression, including adjustment for PAM50 molecular subtype and immune cell signatures. Innate immune-sensing signatures were strongly correlated with interferon signaling (r = 0.73) and macrophage-associated signatures (r = 0.77), indicating a coordinated inflammatory program. Innate immune sensing was moderately associated with EMT (r = 0.48), invasion (r = 0.45), and metastasis-related transcriptional programs (r = 0.48). In multivariable models, innate immune sensing remained associated with EMT after adjustment for molecular subtype and immune cell signatures (β = 0.17, P < 0.001), while macrophage signatures were the dominant predictors (β = 0.51, P < 2 × 10-16) and CD8 signatures were inversely associated (β = -0.14, P < 0.001). No association with overall survival was observed. Innate immune-sensing signatures are associated with macrophage-driven EMT programs in breast cancer, consistent with activation of inflammatory pathways within the tumor microenvironment.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты